MoonLake Immunotherapeutics (MLTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MLTX MoonLake Immunotherapeutics

Watchlist

43.210
-0.390-0.89%

Close Feb 14 16:00 ET

43.210
0.0000.00%

Post 16:20 ET

2.72BMarket Cap-34.02P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely
Yahoo FinanceFeb 11 05:19 ET
Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?
Simply Wall StJan 20 07:52 ET
Apple, Rivian, Cloudflare, Novo Nordisk, Qorvo, SLB, J.B. Hunt: Biggest Stock Movers
Barron'sJan 17 09:56 ET · Movers
Today's Pre-Market Movers and Top Ratings | QRVO, MLTX, NET and More
Movers and ShakersJan 17 09:01 ET
Top Premarket Gainers
MT NewswiresJan 17 08:00 ET
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $82
Moomoo NewsJan 17 06:33 ET · Ratings

Comments

Movers and Shakers

Jan 17 08:01

Columns Today's Pre-Market Movers and Top Ratings | QRVO, MLTX, NET and More

Morning Movers
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...

Meltyy

Jan 24, 2024 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Meltyy

Jan 3, 2024 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Oct 16, 2023 06:34

MoonLake's CEO expresses confidence in 120mg being the optimal dose and highlights the drug's improved durability of response compared to Humira in other studies.

MoonLake Stock Rises After Skin Disorder Drug Shows Promise in Phase 2 Trial

Weight-loss drugmakers report strong earnings: Boon or bane?

Rivera

Aug 16, 2023 07:21

Caming up

$MoonLake Immunotherapeutics (MLTX.US)$

MLTX MoonLake Immunotherapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks